| Journal | Frontiers in neurology |
| Study Type | Clinical Study |
| Population | Human participants |
This consensus from Italian neurologists addresses a growing clinical challenge: managing persistent symptoms and silent progression in MS patients who appear stable on high-efficacy therapies. The focus on endocannabinoid system enhancement represents a shift toward treating residual disease rather than just preventing relapses.
Italian neurologists convened to develop a treatment algorithm for relapse-free multiple sclerosis patients experiencing ongoing symptoms despite high-efficacy therapies. The consensus proposes enhancing the endocannabinoid system through cannabinoid medications combined with lifestyle interventions including diet and exercise to address spasticity and associated residual symptoms. This represents expert clinical opinion rather than controlled trial data, focusing on the reality that many MS patients continue to experience progression and symptoms even when relapse-free on modern therapeutics.
“I appreciate this pragmatic approach to a real clinical gap – patients stable on disease-modifying therapies but still struggling with spasticity and quality of life. The algorithm provides structure for something many of us are already doing case-by-case.”
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
FAQ
Who developed this MS treatment algorithm, and for which patients?
A group of Italian neurologists developed the algorithm through a consensus process, published in Frontiers in Neurology. It is intended for people with multiple sclerosis who are relapse-free on high-efficacy therapies but still experience ongoing symptoms.
What approach does the consensus propose for residual MS symptoms?
The consensus proposes enhancing the endocannabinoid system by combining cannabinoid medications with lifestyle interventions, including diet and exercise. The aim of this combined approach is to address spasticity and associated residual symptoms in patients who otherwise appear stable on their therapy.
Why focus on MS patients who are no longer having relapses?
Many people with MS continue to experience symptoms and disease progression even when they are relapse-free on modern therapies. The article describes persistent symptoms and silent progression in patients who appear stable as a growing clinical challenge, and it frames this consensus as a shift toward treating residual disease rather than only preventing relapses.
Is this MS consensus based on controlled clinical trial results?
No. The article describes the consensus as expert clinical opinion rather than controlled trial data. It offers a structured treatment algorithm from neurologists, but it does not report trial results showing how well cannabinoid medications combined with diet and exercise work for residual MS symptoms.
Get the next evidence review in your inbox
Plain-language summaries of the newest cannabis research, written by a physician. Free to read, and you can unsubscribe at any time.
Join the growing cannabis community. Free. One-click subscribe. Delivered by Substack.
